TrialNaunyn-Schmiedeberg's archives of pharmacology2026
Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a candidate biosimilar INTP23.1 with EU and US‑approved denosumab reference products in healthy adult men.
Steve Fenwick et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.